Revive Therapeutics Announces Proposed Private Placement
Rhea-AI Summary
Revive Therapeutics (OTCQB:RVVTF) announced a proposed non-brokered private placement of up to 31,250,000 units at $0.032 per unit, for maximum gross proceeds of about $1,000,000.
Each unit includes one common share and a three‑year warrant exercisable at $0.05, with proceeds earmarked for working capital.
Positive
- Potential capital raise of up to $1,000,000 for working capital
- Investors receive full warrant coverage with $0.05 exercise price for 36 months
- Ability to close the private placement in multiple tranches offers flexibility
Negative
- Issuance of up to 31,250,000 new units may dilute existing shareholders
- Finder fees and broker warrants equal to 8.0% increase capital-raising cost
- All securities carry a four-month-and-one-day hold, limiting immediate liquidity
News Market Reaction – RVVTF
In the Jun 29 session, RVVTF gained 4.74%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
TORONTO, ON / ACCESS Newswire / June 26, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on infectious diseases and medical countermeasures, announces that it is proposing to arrange a private placement of up to 31,250,000 units of the Company ("Units"), at a price of
Each Unit will consist of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant will entitle the holder to acquire one Common Share at an exercise price of
Certain finders will be entitled to a cash fee equal to
The gross proceeds from the Private Placement will be used for working capital purposes. The proposed Private Placement may close in one or more tranches.
Closing of the Private Placement is subject to customary closing conditions and the Company intends to close as soon as practicable. All of the securities will be subject to a hold period of four months and one day from the date of issuance.
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug-development efforts to take advantage of regulatory incentives that may be available for important unmet medical needs. The Company is currently exploring the use of Bucillamine for infectious diseases, nerve agent exposure and long COVID, among other potential applications. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the CSE nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "may", "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive's current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes, but are not limited to: statements with respect to the use of proceeds and intended closing of the Private Placement.
Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading "Risk Factors" in the Company's management's discussion and analysis for the three and nine months ended March 31, 2026 , dated May 29, 2026, which is available on the Company's profile at www.sedarplus.ca.
SOURCE: Revive Therapeutics Ltd.
View the original press release on ACCESS Newswire